Cas:1006436-44-7 1-Methyl-3-(trifluoromethyl)-1H-pyrazol-4-amine manufacturer & supplier

Chemical Name:1-Methyl-3-(trifluoromethyl)-1H-pyrazol-4-amine

CAS.NO:1006436-44-7

Synonyms:1H-Pyrazol-4-amine, 1-methyl-3-(trifluoromethyl)-;1-methyl-3-(trifluoromethyl)pyrazol-4-amine;1-Methyl-3-(trifluoromethyl)-1H-pyrazol-4-amine

Molecular Formula:C₅H₆F₃N₃

Molecular Weight:165.116

HS Code:2933199090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:225.0±35.0 °C at 760 mmHg

Density:1.5±0.1 g/cm3

Index of Refraction:1.493

PSA:43.84000

Exact Mass:165.051376

LogP:1.20

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1H-Pyrazol-4-amine, 1-methyl-3-(trifluoromethyl)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Methyl-3-(trifluoromethyl)-1H-pyrazol-4-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-Pyrazol-4-amine, 1-methyl-3-(trifluoromethyl)- Use and application,1-methyl-3-(trifluoromethyl)pyrazol-4-amine technical grade,usp/ep/jp grade.

Related News: A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. 1-Methyl-3-(trifluoromethyl)-1H-pyrazol-4-amine manufacturer Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). 1-Methyl-3-(trifluoromethyl)-1H-pyrazol-4-amine supplier After this long manufacturing process, it is purified until it reaches a very high degree of purity and finally becomes an API. 1-Methyl-3-(trifluoromethyl)-1H-pyrazol-4-amine vendor Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). 1-Methyl-3-(trifluoromethyl)-1H-pyrazol-4-amine factory With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow.